Skip to main content
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2005 Apr;42(4):e22. doi: 10.1136/jmg.2004.022327

No MSH6 germline mutations in breast cancer families with colorectal and/or endometrial cancer

P Vahteristo, S Ojala, A Tamminen, J Tommiska, H Sammalkorpi, S Kiuru-Kuhlefelt, H Eerola, L Aaltonen, K Aittomaki, H Nevanlinna
PMCID: PMC1736038  PMID: 15805151

Abstract

Background: The genetic background in breast cancer families with colorectal and/or endometrial cancer is mostly unknown. The functional connection between MSH6 and the known breast cancer predisposition gene product BRCA1 suggests that the MSH6 gene may also play a role in breast cancer predisposition.

Methods: We analysed 38 breast cancer families with colorectal and/or endometrial cancer for germline mutations in MSH6.

Results: No disease associated mutations were detected among the breast cancer families. However, mutation analysis revealed a Glu995STOP mutation in an atypical HNPCC family. The same mutation was found in a patient with both breast and colorectal carcinoma in our previous study, and haplotype analysis confirmed a common ancestral origin. The Glu995STOP mutation was further examined in an extensive series of 245 colorectal and 142 breast carcinoma patients with a family history of breast, colorectal, and/or endometrial carcinoma, and in 268 healthy population controls, but none was found to carry the mutation.

Conclusions: Our results suggest that MSH6 may not be the underlying gene in breast cancer families with a history of colorectal and/or endometrial cancer. The Glu995STOP founder mutation is not a familial breast cancer predisposition allele and makes only a limited contribution to colorectal cancer burden in Finland.

Full Text

The Full Text of this article is available as a PDF (88.3 KB).


Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES